Търсене

Transparency

Прозрачност Takeda - Transparency Disclosure Report 2018 (PDF format, 184 Kb) Methodological Note 2018 (PDF format, 299 Kb)       ) Disclosures Archive ...

www.takeda.com/bg-bg/who-we-are/company-information/building-trust/transparency/

Глобално развитие: 1985-1999 1985-1999|Информация за компанията|Takeda Pharmaceutical Company Limited През 1781 г. Чобей Такеда I (Chobei Takeda I) започва продажбата на традиционни японски и китайс...

www.takeda.com/bg-bg/who-we-are/company-information/history/1985-1999/

Interaction with Patients Organizations

Взаимодействие с пациентски организации Takeda - Patient Organizations Контакти: Takeda Bulgaria, 1680 София, бул. България 58, вх. С, ет. 6, офис 21 Interactions with Patient Organizations  ...

www.takeda.com/bg-bg/who-we-are/company-information/building-trust/interaction-with-patients-organizations/

Building Trust

Изграждане на доверие Такеда - Доверително доверие Takeda Global Научете повече за компанията ни   Takeda Global Website Takeda се ангажира с непрекъснати усилия за изграждане на доверие и ре...

www.takeda.com/bg-bg/who-we-are/company-information/building-trust/

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD Anti-inflammatory treatment aimed at patients with severe...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomeds-novel-anti-inflammatory-therapy-daxas-roflumilast-receives-marketing-authorisation-in-the-european-union-for-patients-with-copd/

Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada

Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada For further information Media: General phone: +41 44 555 15 10Beatrix Benz, phone:&n...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomed-and-merck--co.-inc.-announce-commercialization-agreements-for-daxas-in-europe-and-canada/

Nycomed’s first quarter 2010 results confirm the direction

Nycomed’s first quarter 2010 results confirm the direction Strong growth of Key Products and in emerging markets. Impact of pantoprazole's patent expiry in May 2009 as expected. Total net turnover d...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomeds-first-quarter-2010-results-confirm-the-direction/

GE Healthcare and Nycomed to form joint venture to sell, market and distribute medical diagnostic contrast agents in Russia and CIS

GE Healthcare and Nycomed to form joint venture to sell, market and distribute medical diagnostic contrast agents in Russia and CIS For further information Media: General phone: +41 44 555 ...

www.takeda.com/bg-bg/newsroom/news-releases/2010/ge-healthcare-and-nycomed-to-form-joint-venture-to-sell-market-and-distribute-medical-diagnostic-contrast-agents-in-russia-and-cis/

Adcetris

Learn more

www.takeda.com/bg-bg/what-we-do/prescribed/adcetris/

Entyvio

Learn more

www.takeda.com/bg-bg/what-we-do/prescribed/entyvio/

Резултати от търсенето